FEB 22, 2018 09:00 AM PST
Integrated Interrogation of Oncogenic Signaling Pathways, Immunology, and Heterogeneity in Cancer
Presented at the Drug Discovery 2018 Virtual Event
SPONSORED BY: Nanostring Technologies
1 1 23

  • Deputy Chairman and Associate Professor in the Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
      Dr. Davies is the Deputy Chairman and associate professor in the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, with joint appointments in the Departments of Systems Biology and Translational Molecular Pathology. Dr. Davies is a physician-scientist whose research utilizes integrated approaches to study the regulation and clinical significance of oncogenic signaling networks in cancer, particularly in therapeutic resistance and in the molecular pathogenesis of brain metastases. Dr. Davies has been the principal investigator of both individual and team science peer-reviewed grants from several organizations, including the National Cancer Institute (NCI), the American Society of Clinical Oncology (ASCO), the Melanoma Research Alliance, and the Melanoma Research Foundation. He has served as the principal investigator of several clinical trials for patients with metastatic melanoma, and has authored or co-authored >100 manuscripts in peer-reviewed journals including Cell, Cancer Cell, Science, Cancer Discovery, Cancer Research, and Clinical Cancer Research. Dr. Davies is a member of the American Society for Clinical Investigation, the Melanoma Research Foundation Breakthrough Consortium, and the International Melanoma Working Group.
    • Senior Vice President of Research and Development, NanoString Technologies
        Since April 2012, Joe Beechem has led NanoString Technologies in its pursuit of next-generation immune-oncology. With deep expertise in genetic analysis, sequencing, and research, Dr. Beechem has directed the design and development of multiple genetic analysis technologies including various sequencing platforms.


      The field of melanoma has been transformed by the parallel development of effective immune and targeted therapies.  There is now strong evidence of cross-talk between oncogenic signaling pathways in tumors and the anti-tumor immune response, supporting the need for concurrent evaluation of immune and molecular phenotypes in patient samples.  Further, there is growing evidence of the heterogeneity of immune and molecular phenotypes between, and even within, tumors.  This webinar will explore oncogenic signaling pathways, resulting immune responses and the impact of heterogeneity in cancer. Examples of studies will be presented in which Digital Spatial Profiling has been used to assess immune and molecular features to make insights into the pathogenesis of melanoma.

      Show Resources
      Loading Comments...